Thiazole

Thiazoles are widely recognised as a privileged scaffold in drug discovery due to their exceptional breadth of biological activity and favourable physicochemical profile. The thiazole nucleus is found in a myriad of natural products and synthetic compounds, and more than 30 approved antibiotics contain the thiazole moiety, particularly in the form of aminothiazole, with several being extensively used to treat infections caused by Gram-negative pathogens. The sulphur atom confers a degree of lipophilicity and polarisability that enhances target binding, whilst the basic nitrogen provides a hydrogen bond acceptor that supports protein interactions, and the aromatic character of the ring provides metabolic stability and allows productive π-stacking and electrostatic contacts with biological targets. The unique electronic structure of the thiazole ring facilitates strong interactions with various biological targets, enabling modulation of key enzymes and signalling pathways involved in disease progression, with derivatives showing potent antimicrobial, anticancer, anti-inflammatory, and antioxidant properties across multiple therapeutic areas.

In drug design, the aminothiazole motif is particularly prevalent as a kinase-binding pharmacophore, where the 2-amino group and the ring nitrogen engage in critical hydrogen bond networks within the ATP-binding hinge region of tyrosine and serine/threonine kinases. Several thiazole-containing anticancer drugs are employed to treat different types of cancer, including dasatinib and dabrafenib, as well as ritonavir and cobicistat among antiviral agents, and edoxaban and mirabegron among cardiovascular drugs, reflecting the versatility of the scaffold across therapeutic classes.

Dasatinib (Sprycel, Bristol Myers Squibb), approved by the FDA in June 2006 for the treatment of chronic myeloid leukaemia, is a dual Src/BCR-Abl kinase inhibitor whose aminothiazole-5-carboxamide core makes direct hydrogen bond contacts with the ABL kinase hinge region, and its ability to bind multiple conformations of BCR-Abl confers activity against many imatinib-resistant mutants. Tovorafenib (Ojemda, Day One Biopharmaceuticals), granted FDA accelerated approval in April 2024 as the first-in-class type II RAF inhibitor and the first systemic therapy approved for relapsed or refractory BRAF-altered pediatric low-grade glioma, incorporates a central 1,3-thiazole ring confirmed in the FDA label IUPAC name as 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-4-pyrimidinecarboxamide, where the thiazole bridges the pyrimidine carboxamide and chloropyridyl carboxamide arms of the molecule and is critical to its brain-penetrant RAF inhibitory activity.

Our range of Thiazoles features novel substitutions and the incorporation of synthetically tractable functional groups such as boronic acids and esters, amines, carboxylic acids, ketones, hydroxyls and halogens to enable expedient synthetic strategies.

Please examine a selection of Thiazoles in our catalogue. The full range can be found using the substructure feature of our Search tools.